High dosesof CBP/p300 inhibitors have been used in cancer research involvingserious adverse effects.30 In contrast,we expect that low doses (1/10 to 1/100 in comparison to oncology)of bromodomain inhibitor GNE-049 (or KAT inhibitor A-485) would bewell-tolerated and have more favorable pharmacokinetics and toxicityprofiles. The gene discussed is EP300; the disease is cancer.